Revvity AI Stock Analysis
Revvity (PKN) AI Stock Analysis
Revvity
(XETRA:PKN)
No summary available
Revvity (PKN) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 16.62B
- Dividend Yield
- 0.18%
- Average Volume (3M)
- 114
- Price to Earnings (P/E)
- 66.2
- Beta (1Y)
- 0.49
- Revenue Growth
- -0.66%
- EPS Growth
- 7.12%
- Country
- Germany
- Employees
- 11,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Revvity Business Overview & Revenue Model
Company Description
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters...
Revvity Earnings Call Summary
The call was strongly positive. Highlights significantly outweighed the limited challenges, with broad-based Q3 growth, improving pharma and biotech demand, expanding AI-related demand, strong cash generation, margin expansion, and multiple upward guidance revisions. The main negatives were FX pressure, APAC and China reproductive-health challenges, the pending China immunodiagnostics divestiture, and expected moderation in certain Q4 growth rates.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Revvity now expects pro forma organic growth of approximately 5% in both the fourth quarter and for the full year, with FX contributing approximately 50 basis points for the full year, ACD/Labs contributing approximately 75 basis points, and 2026 pro forma revenue being approximately $2.86 billion; full year operating margins are expected to be 28.8%, net interest expense approximately $88 million, the adjusted tax rate 18%, shares outstanding 112 million, and pro forma adjusted EPS in the range of $5.40 to $5.45, which equates to approximately 12% growth year over year. For the fourth quarter, the midpoint of expected revenue is approximately $755 million, pro forma adjusted operating margins are expected to be slightly above 32%, net interest expense approximately 22 million, the adjusted tax rate approaching 20%, shares around 112 million, and the midpoint of pro forma adjusted EPS guidance $1.60; life sciences instruments are expected to grow high single digits, reagents mid single digit, Signals software closer to a mid-teens number, diagnostics mid single digits overall, immunodiagnostics up high single digits, and reproductive health at low single digits.
Revvity Risk Analysis
Revvity disclosed 24 risk factors in its most recent earnings report. Revvity reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksRevvity Peers Comparison
Overall Rating
QGEN77Outperform
TMO76.9Outperform
A75Outperform
ILMN75Outperform
DHR73Outperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $10.29B | 26.79 | 11.04% | 5.30% | 2.17% | -5.13% | |
| 77Outperform | $256.15B | 36.40 | 13.31% | 0.27% | 8.27% | 9.59% | |
| 75Outperform | $48.75B | 34.01 | 20.47% | 0.59% | 8.60% | 19.07% | |
| 75Outperform | $29.94B | 33.88 | 31.45% | ― | 6.00% | 31.48% | |
| 73Outperform | $161.75B | 37.78 | 8.18% | 0.66% | 5.52% | 25.53% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:PKN | Revvity, Inc. | 136.00 | 57.00 | 72.15% | |
| A | Agilent Technologies | 172.22 | 28.90 | 20.16% | |
| DHR | Danaher Corporation | 225.77 | 4.99 | 2.26% | |
| ILMN | Illumina | 202.61 | 82.49 | 68.67% | |
| QGEN | Qiagen | 49.75 | 5.64 | 12.80% | |
| TMO | Thermo Fisher Scientific | 686.79 | 115.01 | 20.11% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
